This company listing is no longer active
Delta 9 Cannabis Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Delta 9 Cannabis's earnings have been declining at an average annual rate of -51.6%, while the Pharmaceuticals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 20.1% per year.
Belangrijke informatie
-51.6%
Groei van de winst
-45.6%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 7.3% |
| Inkomstengroei | 20.1% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -27.7% |
| Laatste winstupdate | 31 Mar 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Delta 9 Cannabis geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 71 | -20 | 28 | 0 |
| 31 Dec 23 | 71 | -18 | 28 | 0 |
| 30 Sep 23 | 71 | -22 | 30 | 0 |
| 30 Jun 23 | 68 | -24 | 31 | 0 |
| 31 Mar 23 | 68 | -26 | 32 | 0 |
| 31 Dec 22 | 63 | -27 | 31 | 0 |
| 30 Sep 22 | 63 | -21 | 29 | 0 |
| 30 Jun 22 | 62 | -14 | 27 | 0 |
| 31 Mar 22 | 62 | -11 | 26 | 0 |
| 31 Dec 21 | 62 | -11 | 25 | 0 |
| 30 Sep 21 | 59 | -8 | 24 | 0 |
| 30 Jun 21 | 57 | -12 | 22 | 0 |
| 31 Mar 21 | 54 | -13 | 22 | 0 |
| 31 Dec 20 | 52 | -6 | 21 | 0 |
| 30 Sep 20 | 48 | -8 | 18 | 0 |
| 30 Jun 20 | 42 | -4 | 18 | 0 |
| 31 Mar 20 | 38 | -3 | 17 | 0 |
| 31 Dec 19 | 32 | 11 | 17 | 0 |
| 30 Sep 19 | 26 | 12 | 19 | 0 |
| 30 Jun 19 | 21 | 11 | 19 | 0 |
| 31 Mar 19 | 13 | 10 | 17 | 0 |
| 31 Dec 18 | 8 | -8 | 14 | 0 |
| 30 Sep 18 | 3 | -12 | 10 | 0 |
| 30 Jun 18 | 2 | -11 | 7 | 0 |
| 31 Mar 18 | 1 | -9 | 5 | 0 |
| 31 Dec 17 | 1 | -8 | 3 | 0 |
| 30 Sep 17 | 1 | -2 | 2 | 0 |
| 30 Jun 17 | 1 | -2 | 2 | 0 |
| 31 Mar 17 | 1 | -1 | 2 | 0 |
| 31 Dec 16 | 0 | -1 | 2 | 0 |
| 31 Dec 15 | 1 | -1 | 1 | 0 |
Kwaliteitswinsten: V5D1 is currently unprofitable.
Groeiende winstmarge: V5D1 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: V5D1 is unprofitable, and losses have increased over the past 5 years at a rate of 51.6% per year.
Versnelling van de groei: Unable to compare V5D1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: V5D1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Rendement op eigen vermogen
Hoge ROE: V5D1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.